Thomas A. Hope
Nuclear medicine physician who led the trials that got PSMA PET approved in the United States.
Radiologist whose prospective studies of 68Ga-PSMA-11 PET at UCSF and UCLA supported the first FDA approval of PSMA PET in 2020. Leads theranostics research and PSMA radioligand dosimetry work.
Pages like this
not linked directly; found by shared links- PersonRahul Aggarwal
Shares UCSF Helen Diller Family Comprehensive Cancer Center, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares PET (positron emission tomography), PSMA, PSMA PET, Radioligand therapy (beta emitters).
- CompanyClarity Pharmaceuticals
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonJeremie Calais
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- TargetGRPR (gastrin-releasing peptide receptor)
Shares PET (positron emission tomography), Radioligand therapy (beta emitters), Prostate cancer.
- ProductGallium-68 gozetotide (PSMA-11)
Shares UCSF Helen Diller Family Comprehensive Cancer Center, PSMA, PSMA PET, Prostate cancer.
- PersonPeter Bartenstein
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- ProductFlotufolastat F-18
Shares PSMA, PSMA PET, Prostate cancer.